Iveric Bio announces FDA approval for IZERVAY™️️
Congratulations to Iveric Bio for their FDA approval for IZERVAY™️️, a new treatment for...
read Details
The team at Atara Biotherapeutics announced EU Approval on their allogeneic T-cell therapy to treat adult and pediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus (EBV) positive post-transplant lymphoproliferative disease (PTLD).
Modality Solutions supported Atara by developing short-term shipping solutions, a transport validation and shipper qualification strategy. We are honored to be a part of the first-ever globally approved allogeneic (donor-derived) T-cell immunotherapy.
Read the full Atara Press Release, or check out our case study on the cold chain engineering work Modality Solutions provided to support Atara’s approval.
“Modality Solutions approach to leveraging integrated technologies to orchestrate and supply commercial activities directly impacted our success.” – VP, Technical Operations, Atara
Congratulations to Iveric Bio for their FDA approval for IZERVAY™️️, a new treatment for...
read DetailsCongratulations to Incyte on their FDA approval for Zynyz™, a treatment for adults with metastatic...
read DetailsCongratulations to Amicus Therapeutics for their European Commission approval for Pombiliti™ in patients with Late-Onset...
read Details